Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clostridium difficile (C. diff)
Biotech
Vedanta's live bacteria cocktail fails phase 2 colitis trial
Vedanta is reorienting resources toward lead candidate VE303, which is chasing the tail of Seres’ Vowst in treating recurrent C. diff infections.
Darren Incorvaia
Aug 13, 2025 1:48pm
Pfizer's embattled obesity program loses another GLP-1 drug
Aug 5, 2025 8:51am
Xeno's gastric-bypass pill alternative to be tested for C. diff
Jan 6, 2025 7:15am
mRNA vaccine protects mice from deadly C. diff infections
Oct 4, 2024 1:08pm
Crestone’s antibiotic beats vancomycin at treating C. diff
Sep 5, 2024 3:11pm
Chasing Seres, Vedanta bags $107M to run phase 3 C. diff trial
Apr 25, 2023 9:40am
